Veradermics, Inc SEC filings MANE

Veradermics, Inc has 97 filings in SEC EDGAR's recent list, going back to Oct 9, 2020. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Veradermics, Inc SEC filings
Form Description Filed Period
8-K Current report
Regulation FD disclosure, Other events
Oct 19, 2026 Oct 19, 2026
SCHEDULE 13G Ownership over 5% (passive) Oct 13, 2026 —
4 Insider transaction Sep 3, 2026 Sep 1, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 21, 2026 —
4 Insider transaction Aug 21, 2026 Aug 19, 2026
3 Initial insider ownership Aug 20, 2026 Aug 10, 2026
144 Notice of proposed sale Aug 19, 2026 —
144 Notice of proposed sale Aug 19, 2026 —
4 Insider transaction Aug 18, 2026 Aug 17, 2026
4 Insider transaction Aug 18, 2026 Aug 17, 2026
144 Notice of proposed sale Aug 17, 2026 —
144 Notice of proposed sale Aug 17, 2026 —
EFFECT Filing Aug 14, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 14, 2026 —
144/A Filing Aug 14, 2026 —
4 Insider transaction Aug 14, 2026 Aug 12, 2026
424B3 Prospectus Aug 14, 2026 —
144 Notice of proposed sale Aug 12, 2026 —
144 Notice of proposed sale Aug 12, 2026 —
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 11, 2026 Aug 11, 2026
S-1 Registration statement Aug 7, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 6, 2026 —
8-K Current report
Regulation FD disclosure, Other events
Jul 15, 2026 Jul 15, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
D Filing May 15, 2026 —
10-Q Quarterly report May 12, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 12, 2026 May 12, 2026
SCHEDULE 13G Ownership over 5% (passive) May 7, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) May 5, 2026 —
4 Insider transaction May 5, 2026 May 1, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) May 5, 2026 —
SCHEDULE 13D Ownership over 5% (active) May 5, 2026 —
3 Initial insider ownership May 5, 2026 May 1, 2026
8-K Current report
Material agreement, Unregistered share sale
May 1, 2026 May 1, 2026
424B4 Prospectus Apr 30, 2026 —
FWP Free writing prospectus Apr 30, 2026 —
EFFECT Filing Apr 29, 2026 —
S-1MEF Filing Apr 29, 2026 —
FWP Free writing prospectus Apr 27, 2026 —
CORRESP Letter to the SEC Apr 27, 2026 —
CORRESP Letter to the SEC Apr 27, 2026 —
S-1 Registration statement Apr 27, 2026 —
8-K Current report
Results of operations
Apr 27, 2026 Apr 27, 2026
8-K Current report
Regulation FD disclosure, Other events
Apr 27, 2026 Apr 27, 2026
UPLOAD Letter from the SEC Apr 7, 2026 —
DRS Filing Apr 6, 2026 —
10-K Annual report Mar 30, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 30, 2026 Mar 30, 2026
4/A Form 4/a Feb 27, 2026 Feb 3, 2026
SCHEDULE 13D Ownership over 5% (active) Feb 12, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 12, 2026 —
SCHEDULE 13D Ownership over 5% (active) Feb 11, 2026 —
SCHEDULE 13D Ownership over 5% (active) Feb 11, 2026 —
4 Insider transaction Feb 9, 2026 Feb 4, 2026
3 Initial insider ownership Feb 9, 2026 Feb 4, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 5, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
4 Insider transaction Feb 5, 2026 Feb 3, 2026
S-8 Employee stock plan registration Feb 5, 2026 —
8-K Current report
Bylaw or fiscal year change
Feb 5, 2026 Feb 5, 2026
424B4 Prospectus Feb 4, 2026 —
CERT Nyse certification Feb 4, 2026 —
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
3 Initial insider ownership Feb 3, 2026 Feb 3, 2026
S-1MEF Filing Feb 3, 2026 —
8-A12B Filing Feb 3, 2026 —
FWP Free writing prospectus Feb 3, 2026 —
EFFECT Filing Jan 30, 2026 —
S-1/A Amended registration statement Jan 28, 2026 —
S-1 Registration statement Jan 9, 2026 —
D Filing Oct 28, 2025 —
DRS Filing Oct 27, 2025 —
D Filing Dec 10, 2024 —
D Filing May 1, 2023 —
D/A Filing Oct 7, 2021 —
D Filing Oct 6, 2021 —
D Filing Oct 9, 2020 —

Showing 97 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MANE (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New Haven, CT
SEC filer status
, Emerging growth company
SEC CIK
1827635

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.